vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Commercial Vehicle Group, Inc. (CVGI). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $154.8M, roughly 1.6× Commercial Vehicle Group, Inc.). On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -5.2%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $8.7M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -10.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
WABCO Holdings, Inc. was a U.S.-based provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. In 2007, the Vehicle Control Systems was spun off as WABCO Holdings Inc., an American provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. Their products are present in many commercial vehicles such as trucks, buses, trailers and off-highway vehicles but they ...
ANIP vs CVGI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $154.8M |
| Net Profit | $27.5M | — |
| Gross Margin | — | 9.7% |
| Operating Margin | 14.1% | -1.2% |
| Net Margin | 11.1% | — |
| Revenue YoY | 29.6% | -5.2% |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $154.8M | ||
| Q3 25 | $227.8M | $152.5M | ||
| Q2 25 | $211.4M | $172.0M | ||
| Q1 25 | $197.1M | $169.8M | ||
| Q4 24 | $190.6M | $163.3M | ||
| Q3 24 | $148.3M | $171.8M | ||
| Q2 24 | $138.0M | $193.7M | ||
| Q1 24 | $137.4M | $194.6M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $-7.1M | ||
| Q2 25 | $8.5M | $-4.8M | ||
| Q1 25 | $15.7M | $-4.3M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $9.5M | ||
| Q2 24 | $-2.3M | $-1.6M | ||
| Q1 24 | $18.2M | $2.9M |
| Q4 25 | — | 9.7% | ||
| Q3 25 | — | 10.5% | ||
| Q2 25 | — | 11.4% | ||
| Q1 25 | — | 10.5% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 9.6% | ||
| Q2 24 | — | 10.6% | ||
| Q1 24 | — | 11.9% |
| Q4 25 | 14.1% | -1.2% | ||
| Q3 25 | 15.9% | -0.7% | ||
| Q2 25 | 6.6% | 0.5% | ||
| Q1 25 | 13.3% | 0.8% | ||
| Q4 24 | -2.3% | -3.2% | ||
| Q3 24 | -13.8% | -0.6% | ||
| Q2 24 | 3.7% | 0.5% | ||
| Q1 24 | 14.8% | 2.3% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | -4.6% | ||
| Q2 25 | 4.0% | -2.8% | ||
| Q1 25 | 8.0% | -2.5% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 5.5% | ||
| Q2 24 | -1.7% | -0.8% | ||
| Q1 24 | 13.2% | 1.5% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | — | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | — | ||
| Q2 24 | $-0.14 | $-0.05 | ||
| Q1 24 | $0.82 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | — |
| Total DebtLower is stronger | — | $104.9M |
| Stockholders' EquityBook value | $540.7M | $133.4M |
| Total Assets | $1.4B | $391.7M |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — | ||
| Q1 24 | $228.6M | — |
| Q4 25 | — | $104.9M | ||
| Q3 25 | — | $108.2M | ||
| Q2 25 | — | $118.2M | ||
| Q1 25 | — | $117.4M | ||
| Q4 24 | — | $135.5M | ||
| Q3 24 | — | $128.8M | ||
| Q2 24 | — | $142.0M | ||
| Q1 24 | — | $155.7M |
| Q4 25 | $540.7M | $133.4M | ||
| Q3 25 | $505.8M | $136.5M | ||
| Q2 25 | $436.8M | $142.6M | ||
| Q1 25 | $418.6M | $136.7M | ||
| Q4 24 | $403.7M | $135.6M | ||
| Q3 24 | $405.9M | $179.3M | ||
| Q2 24 | $455.8M | $169.6M | ||
| Q1 24 | $452.0M | $175.5M |
| Q4 25 | $1.4B | $391.7M | ||
| Q3 25 | $1.4B | $400.3M | ||
| Q2 25 | $1.3B | $429.8M | ||
| Q1 25 | $1.3B | $419.8M | ||
| Q4 24 | $1.3B | $424.6M | ||
| Q3 24 | $1.3B | $495.3M | ||
| Q2 24 | $920.8M | $503.2M | ||
| Q1 24 | $914.5M | $509.2M |
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.79× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 1.00× | ||
| Q3 24 | — | 0.72× | ||
| Q2 24 | — | 0.84× | ||
| Q1 24 | — | 0.89× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $12.3M |
| Free Cash FlowOCF − Capex | $29.1M | $8.7M |
| FCF MarginFCF / Revenue | 11.8% | 5.6% |
| Capex IntensityCapex / Revenue | 0.5% | 2.3% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $34.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $12.3M | ||
| Q3 25 | $44.1M | $-1.7M | ||
| Q2 25 | $75.8M | $18.9M | ||
| Q1 25 | $35.0M | $15.2M | ||
| Q4 24 | $15.9M | $-26.6M | ||
| Q3 24 | $12.5M | $-17.1M | ||
| Q2 24 | $17.4M | $12.6M | ||
| Q1 24 | $18.3M | $-2.4M |
| Q4 25 | $29.1M | $8.7M | ||
| Q3 25 | $38.0M | $-3.5M | ||
| Q2 25 | $71.8M | $17.4M | ||
| Q1 25 | $32.5M | $11.4M | ||
| Q4 24 | $13.5M | $-30.6M | ||
| Q3 24 | $7.7M | $-20.3M | ||
| Q2 24 | $13.0M | $6.4M | ||
| Q1 24 | $13.7M | $-7.4M |
| Q4 25 | 11.8% | 5.6% | ||
| Q3 25 | 16.7% | -2.3% | ||
| Q2 25 | 34.0% | 10.1% | ||
| Q1 25 | 16.5% | 6.7% | ||
| Q4 24 | 7.1% | -18.7% | ||
| Q3 24 | 5.2% | -11.8% | ||
| Q2 24 | 9.4% | 3.3% | ||
| Q1 24 | 10.0% | -3.8% |
| Q4 25 | 0.5% | 2.3% | ||
| Q3 25 | 2.7% | 1.2% | ||
| Q2 25 | 1.9% | 0.9% | ||
| Q1 25 | 1.3% | 2.2% | ||
| Q4 24 | 1.3% | 2.4% | ||
| Q3 24 | 3.2% | 1.9% | ||
| Q2 24 | 3.2% | 3.2% | ||
| Q1 24 | 3.3% | 2.6% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1.79× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | -0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CVGI
| Global Seating | $70.7M | 46% |
| Global Electrical Systems | $49.7M | 32% |
| Trim Systems And Components | $34.4M | 22% |
